+ 39 011 76 51 239

info@adreshe.com

Via Vittorio Alfieri, 17

Torino (To)

Follow Us

2010

2010

  • Zaniolo O, Pradelli L. Economic Performance of Dabigatran Etexilate for Primary VTE Prevention Following Total Hip and Knee Replacement Surgery in Italy. ISPOR 13th Annual European Congress, Prague, Czech Republic, 6-9 November, 2010
  • Iannazzo S, Pradelli L, Chiroli S. A Cost-Utility Analysis of Cinacalcet in Secondary Hyperparathyroidism (SHPT) in Five European Countries. ISPOR 13th Annual European Congress, Prague, Czech Republic, 6-9 November, 2010
  • Iannazzo S, Zaniolo O, Giuliani G. A Budget Impact Model for the Economic Assessment of Tocilizumab in the Treatment of Rheumatoid Arthritis Patients in Italy. ISPOR 13th Annual European Congress, Prague, Czech Republic, 6-9 November, 2010
  • Zaniolo O, Iannazzo S, Carsi M. A Cost-Utility Analysis for Tiotropium in the Long Term Treatment of Specific Subgroups of Italian COPD Patients. ISPOR 13th Annual European Congress, Prague, Czech Republic, 6-9 November, 2010
  • Pradelli L, Zaniolo O, Iannazzo S, Eandi M. Parenteral Alanyl-Glutammine in Critically Ill Patients: a Bayesian Meta-Analysis of Published Trials. ISPOR 13th Annual European Congress, Prague, Czech Republic, 6-9 November, 2010
  • Zaniolo O, Carsi M, Patrucco GP, Bellini R. Clinical and Economic Outcomes of Ziconotide Neuromodulation in Italian Cancer Patients. ISPOR 13th Annual European Congress, Prague, Czech Republic, 6-9 November, 2010
  • Iannazzo S, Zaniolo O, Carsi M. Pharmacoeconomic Evaluation of Tiotropium Bromide in the Long Term Treatment of COPD in Italy. ECHE, 8th European Conference on Health Economics, Helsinki, Finland, 7-10 July, 2010 (Poster n. 137)
  • Iannazzo S, Pradelli L, Chiroli S, Pontoriero G, Eandi M. A Cost-Utility Evaluation of Cinacalcet in the Treatment of Secondary Hyperparathyroidism (SHPT): Consistent Results in Three European Countries. XLVII ERA-EDTA CONGRESS, Munich, Germany, 25-28 June, 2010,
2011
2009
No Comments

Sorry, the comment form is closed at this time.